Have a feature idea you'd love to see implemented?
Let us know!
YMAB Y-mAbs Therapeutics Inc
Price (delayed)
$10.1
Market cap
$452.37M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.54
Enterprise value
$385.32M
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product
Highlights
The company's debt fell by 34% YoY and by 16% QoQ
The quick ratio has grown by 30% from the previous quarter but it has contracted by 28% YoY
The net income has contracted by 24% YoY but it has grown by 3% from the previous quarter
YMAB's revenue is down by 9% year-on-year and by 2.3% since the previous quarter
Y-mAbs Therapeutics's equity has decreased by 8% YoY and by 3% from the previous quarter
Key stats
What are the main financial stats of YMAB
Market
Valuations
Earnings
Shares outstanding
44.79M
Market cap
$452.37M
Enterprise value
$385.32M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.87
Price to sales (P/S)
5.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.56
Revenue
$84.55M
EBIT
-$28.46M
EBITDA
-$27.87M
Free cash flow
-$21.88M
Per share
Balance sheet
Liquidity
EPS
-$0.54
Free cash flow per share
-$0.49
Book value per share
$2.07
Revenue per share
$1.89
TBVPS
$2.66
Total assets
$120.92M
Total liabilities
$28.49M
Debt
$1.08M
Equity
$92.43M
Working capital
$73.77M
Debt to equity
0.01
Current ratio
3.92
Quick ratio
3.48
Net debt/EBITDA
2.41
Margins
Efficiency
Dividend
EBITDA margin
-33%
Gross margin
88.8%
Net margin
-28.2%
Operating margin
-33.7%
Return on assets
-18.5%
Return on equity
-24.6%
Return on invested capital
-109.2%
Return on capital employed
-29.8%
Return on sales
-33.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
YMAB stock price
How has the Y-mAbs Therapeutics stock price performed over time
Intraday
-4.17%
1 week
-12.86%
1 month
-30.63%
1 year
92.02%
YTD
48.09%
QTD
-23.19%
Financial performance
How have Y-mAbs Therapeutics's revenue and profit performed over time
Revenue
$84.55M
Gross profit
$75.11M
Operating income
-$28.46M
Net income
-$23.86M
Gross margin
88.8%
Net margin
-28.2%
The company's net margin fell by 36% YoY
The operating margin has contracted by 33% YoY and by 6% from the previous quarter
The net income has contracted by 24% YoY but it has grown by 3% from the previous quarter
YMAB's operating income is down by 20% year-on-year and by 3% since the previous quarter
Growth
What is Y-mAbs Therapeutics's growth rate over time
Valuation
What is Y-mAbs Therapeutics stock price valuation
P/E
N/A
P/B
4.87
P/S
5.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.56
The EPS has contracted by 20% YoY but it has grown by 3.6% from the previous quarter
YMAB's P/B is 20% below its 5-year quarterly average of 6.1 and 11% below its last 4 quarters average of 5.5
Y-mAbs Therapeutics's equity has decreased by 8% YoY and by 3% from the previous quarter
The stock's price to sales (P/S) is 73% less than its 5-year quarterly average of 19.5 and 15% less than its last 4 quarters average of 6.3
YMAB's revenue is down by 9% year-on-year and by 2.3% since the previous quarter
Efficiency
How efficient is Y-mAbs Therapeutics business performance
Y-mAbs Therapeutics's return on equity has decreased by 34% YoY
The ROS has contracted by 33% YoY and by 6% from the previous quarter
The company's return on invested capital rose by 29% YoY and by 3.7% QoQ
Y-mAbs Therapeutics's ROA has decreased by 29% YoY
Dividends
What is YMAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for YMAB.
Financial health
How did Y-mAbs Therapeutics financials performed over time
The total liabilities has contracted by 42% from the previous quarter
The current ratio has grown by 34% from the previous quarter but it has contracted by 26% YoY
The company's debt is 99% lower than its equity
YMAB's debt to equity has plunged by 50% YoY
The company's debt fell by 34% YoY and by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.